Grip Strength on GLP-1: The Number That Matters More Than the Scale

Grip strength is the maximum force your hand can squeeze, measured in kilograms with a device called a hand dynamometer. It sounds trivially simple, and that is exactly why researchers love it. Decades of studies show that hand grip tracks whole-body muscle strength closely enough to serve as a stand-in for it - which is why the European Working Group on Sarcopenia in Older People built its 2019 diagnostic algorithm around grip as the first test (EWGSOP2, *Age and Ageing* 2019).

On a GLP-1 medication, this matters more than usual. Sarcopenia - the medical term for age-related loss of muscle mass and strength - is normally a slow process. Rapid weight loss speeds it up. When you drop weight quickly on semaglutide or tirzepatide, your body does not politely remove fat only. In the body-composition substudy of STEP 1, participants who lost 14.9% of body weight over 68 weeks saw a meaningful share of that come from lean tissue (Wilding et al., *NEJM* 2021). Estimates across the GLP-1 literature generally land in the 25-40% range for lean mass as a proportion of total loss.

Here is the problem: the bathroom scale cannot tell you which kind of tissue left. Neither can your clothes. A woman down 30 pounds who lost 10 of those pounds as muscle looks smaller and feels thrilled - right up until she notices jars are harder to open and stairs leave her winded. Grip strength catches that shift months earlier, because strength declines faster than mass does. Your muscles lose the ability to generate force before they visibly shrink.

That early-warning quality is the whole point. If you are working on [preserving muscle with strength training](/blog/strength-training-on-glp1-how-to-preserve-muscle-while-losing-weight), grip gives you a cheap monthly readout on whether the strategy is working.

For most healthy adult women, grip strength falls somewhere between 25 and 35 kg in the dominant hand, though it varies a lot with age, body size, and training history. The number that actually matters clinically is the low end.

The EWGSOP2 consensus (Cruz-Jentoft et al., *Age and Ageing* 2019) sets the cutoff for probable sarcopenia at:

• •Under 16 kg for women
• •Under 27 kg for men

Below those thresholds, clinicians are advised to investigate further. American data from the Foundation for the NIH Sarcopenia Project uses a slightly higher women's cutoff of 16 kg as well, so the two systems agree closely.

Age shifts the picture. Grip strength typically peaks in the late twenties to mid thirties, holds a plateau through the forties, and then declines roughly 1-2% per year from the fifties onward. Menopause accelerates this - the loss of estrogen affects muscle protein synthesis and neuromuscular function, which is one reason [muscle loss in menopause on a GLP-1 is a double risk](/blog/glp1-menopause-muscle-loss-the-sarcopenia-double-risk).

But the absolute number is less useful than your own trend. A woman who starts at 34 kg and drops to 27 kg has lost 20% of her strength and is still nowhere near the clinical cutoff - yet something clearly went wrong. A woman who has always sat around 22 kg and stays there is fine.

Track the delta, not the threshold. Record your baseline before you start the medication if you can, or as early in treatment as possible. Then compare against yourself.

You need a hand dynamometer, which is a squeeze device with a digital readout. Reliable models cost roughly $20-40 online. That is the entire equipment list.

The standardized protocol used in research is easy to copy:

1. Sit in a chair with a back, feet flat on the floor. 2. Elbow bent at 90 degrees, tucked against your side, forearm neutral (thumb pointing up). 3. Squeeze as hard as you can for 3-5 seconds. Do not swing your arm, lean, or hold your breath. 4. Rest 30-60 seconds. Repeat three times per hand. 5. Record the highest single reading for each hand.

Consistency beats precision. Test at the same time of day - grip is lower first thing in the morning and after a hard workout. Use the same device. Do not test on an injection day if nausea or fatigue is affecting you, because a bad day produces a misleading number.

A reasonable schedule is once a month, on the same calendar date, before your workout rather than after. Log it next to your weight. If you are already [tracking progress beyond the scale](/blog/tracking-progress-on-glp1-in-menopause-beyond-the-scale), grip slots neatly into that dashboard.

One caveat worth naming: grip is a hand and forearm measurement, and conditions like arthritis, carpal tunnel syndrome, or a wrist injury will depress the reading independently of your overall muscle status. If you have any of these, mention it to your clinician so your numbers get interpreted correctly, and consider pairing grip with a second test such as the five-times sit-to-stand.

A falling grip reading is information, not a verdict. In almost every case the fix is the same two levers: eat more protein and lift heavier things.

Protein first. GLP-1s suppress appetite so effectively that many people drift into eating far less protein than they realize. General guidance for adults losing weight is roughly 1.2-1.6 grams of protein per kilogram of body weight per day, and people in a steep deficit often need the upper end. If you weigh 75 kg, that is about 90-120 grams daily. Spreading it across three meals of 30-40 grams works better than one large dinner, because muscle protein synthesis responds to per-meal doses. Our guide to [how much protein you really need on a GLP-1](/blog/protein-on-glp1-how-much-you-really-need) breaks the math down further.

Then resistance training. Walking is excellent for many things, but it does not meaningfully preserve upper-body muscle. You need load. Two or three sessions a week hitting the major movement patterns - a squat or leg press, a hinge or deadlift variation, a push, a pull, and a carry - is sufficient. Progressive overload matters more than volume: the weight should get heavier over time, even if only slightly.

Loaded carries deserve a special mention because they train grip directly. Pick up two heavy dumbbells or a loaded shopping bag in each hand and walk 30-40 metres. Three or four rounds. It is unglamorous and remarkably effective.

Check the medication side too. If nausea or early fullness is making protein genuinely hard to eat, that is worth discussing before you assume it is a discipline problem. Slowing dose escalation, or holding at a dose that works, is a legitimate strategy - see [when to increase and when to hold](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold).

Finally, if grip keeps falling despite adequate protein and consistent lifting, ask your clinician about checking vitamin D, B12, iron, and thyroid function. Deficiencies are common on GLP-1s and all four affect strength.

Yes, and this is where the measurement stops being a fitness metric and starts being a health one. Grip strength is one of the most robustly studied predictors in modern epidemiology.

The landmark analysis is the PURE study (Leong et al., *The Lancet* 2015), which followed nearly 140,000 adults across 17 countries. Each 5 kg reduction in grip strength was associated with a 16% higher risk of death from any cause, a 17% higher risk of cardiovascular death, and a 7% higher risk of heart attack. Grip predicted mortality more strongly than systolic blood pressure did in that dataset.

Subsequent work has linked low grip strength to higher fracture risk, longer hospital stays, slower surgical recovery, and faster cognitive decline. It is not that squeezing a device causes any of this - grip is a proxy for total muscle quality, nutritional status, and neuromuscular health, all of which genuinely drive outcomes.

For someone on a GLP-1, this reframes the goal. The medication is doing something clearly beneficial: in the SELECT trial, semaglutide reduced major cardiovascular events by 20% over roughly 40 months in adults with overweight or obesity and established heart disease (Lincoff et al., *NEJM* 2023). You want to bank that benefit without quietly trading away muscle - because muscle carries its own independent protective effect.

The encouraging part is that grip strength responds to training at every age, including in women in their seventies and eighties. It is not a fixed trait. A few months of consistent resistance work reliably moves the number up.

So weigh yourself if you like. But squeeze the device too. It answers a question the scale cannot.

Grip strength is the cheapest tool in the box, not the only one. Think of it as your monthly smoke alarm, with more detailed tools reserved for when it goes off.

DXA scans are the clinical gold standard for body composition. A dual-energy X-ray absorptiometry scan separates fat mass, lean mass, and bone mineral density with good precision, and it costs roughly $50-150 in most US cities without insurance. If you are on a GLP-1 through menopause, a DXA does double duty because it also gives you a bone density reading - relevant given that women can lose a substantial share of spinal bone density across the menopause transition (SWAN, Greendale et al.). Once a year is plenty.

Bioelectrical impedance scales - the smart scales that estimate body fat - are convenient but noisy. Hydration status alone can swing the reading several percentage points. They are usable for trends over months, useless for week-to-week decisions.

Tape measurements at the waist, hip, thigh, and upper arm cost nothing and catch shape changes the scale misses. A shrinking waist with a stable upper arm is a good sign. A shrinking upper arm alongside falling grip is not.

Functional tests are underrated. The five-times sit-to-stand (how long it takes to rise from a chair five times without using your hands) and the 30-second chair stand both track lower-body strength, which grip does not measure. Under 12 seconds for five reps is a reasonable target for most middle-aged adults.

Stack them sensibly: weight weekly, tape and grip monthly, DXA annually. That combination catches [body recomposition when the scale stalls](/blog/body-recomposition-on-glp1-when-the-scale-stalls) and tells you whether a plateau is actually progress in disguise.